Drugs / HB2198
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07491900 | Mar 2026 → Oct 2027 expected | lupus nephritis, systemic lupus erythematosus | Hinge Bio | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07439263 Comparator | Mar → Aug 2026 overdue | — | Hinge Bio | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-10-13 | Hinge Bio | Regulatory Hinge Bio Announces FDA Clearance of Investigational New Drug Application for HB2198, a Novel B cell-Depleting Agent, for Patients with Systemic Lupus Erythematosus and Lupus Nephritis hingebio.com ↗ |
| 2025-09-04 | Hinge Bio | Results Hinge Bio Expands Leadership Team to Drive Clinical Development of GEM-DIMER™ Programs and Announces Publication in Scientific Reports hingebio.com ↗
We also appreciate the recognition by Scientific Reports of the differentiated efficacy data demonstrated with HB2198 to durably deplete memory B cells, which is evidence of a key mechanism of action for multiple autoimmune indications, including SLE. |
| 2024-11-14 | Hinge Bio | Results Hinge Bio Presents Preclinical Data from its GEM-DIMER™ Programs Targeting B Cell Depletion at the American College of Rheumatology (ACR) Convergence 2024 hingebio.com ↗
The poster presentation will include data from multiple therapeutic programs from Hinge Bio’s proprietary GEM-DIMER platform, including in vivo data from its lead program, HB2198, targeting CD19 and CD20 for B cell depletion. |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB2198 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07491900 ↗ |
| Action | Deplete | “including B-cell depletion kinetics” NCT07439263 ↗ |
| Route | Intravenous | “administered via IV infusion on Day 1” NCT07439263 ↗ |